Volume6, Issue0 (2023) | undefined

Cancer Drug Resistance

Search Log In

Editor-in-Chief: Godefridus J. Peters

Indexing: ESCI, PMC, Scopus, CAS, CNKI, Dimensions, Lens, Embase,

Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)] Submission to first decision: 10 days

Hot Keywords

ResistanceDrug deliveryNanomedicineTumor microenvironmentImmune checkpoint inhibitorsTarget therapyImmunotherapyRadiotherapyFerroptosisPARP inhibitorsMYCABC transportersAutophagyMetabolismMechanismsPrecision medicineExtracellular vesiclesStem cellBiomarkerOvarian cancerRenal cell carcinomaProstate cancerBreast cancerColorectal cancerMyeloid leukemiaNon-small cell lung cancerPancreatic cancerHead and neck cancerSquamous cell carcinomaMitochondria

Home

About

Publish with us

Articles

Special Issues

Special Collections

Volumes

Pre-onlines

Features

Home Articles Special Issues Volumes Webinars Videos

Cancer Drug Resistance

Editor-in-Chief: Godefridus J. Peters

Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]

Submission to first decision: 10 days

Home Articles Special Issues Volumes Webinars Videos

Home Volumes

Volume

Table of Contents (52 articles)

P-glycoprotein (ABCB1) - weak dipolar interactions provide the key to understanding allocrite recognition, binding, and transport

Anna Seelig

Anna Seelig

, Xiaochun Li-Blatter

Pages 1-29

Concomitant medications and circulating tumor cells: friends or foes?

Serena Di Cosimo

Serena Di Cosimo

, Vera Cappelletti

Vera Cappelletti

Pages 30-34

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers

Rachel Bayley, ... Martin R. Higgs

Martin R. Higgs

Pages 35-44

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

Santiago Escrivá-de-Romaní

Santiago Escrivá-de-Romaní

, Cristina Saura

Pages 45-58

Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities

Leonhard H. F. Köhler, ... Bernhard Biersack

Bernhard Biersack

Pages 59-77

Nano-TRAIL: a promising path to cancer therapy

Siri Chandana Gampa, ... SanthiLatha Pandrangi

Pages 78-102

Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance

Alexander M. Scherbakov, ... Mikhail A. Krasil’nikov

Pages 103-115

Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma

Juliana Mota Siqueira

Juliana Mota Siqueira

, ... Maria Fernanda Setúbal Destro Rodrigues

Maria Fernanda Setúbal Destro Rodrigues

Pages 116-137

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment

Yoko Tabe

Yoko Tabe

, Marina Konopleva

Marina Konopleva

Pages 138-150

Targeting regulated cell death pathways in acute myeloid leukemia

Sylvain Garciaz

Sylvain Garciaz

, ... Norbert Vey

Pages 151-168

Anti-BCMA novel therapies for multiple myeloma

Vincenzo Sammartano

Vincenzo Sammartano

, ... Alessandro Gozzetti

Alessandro Gozzetti

Pages 169-181

Heterotypic signaling of cancer-associated fibroblasts in shaping the cancer cell drug resistance

Ramesh Butti, ... Gopinath Prakasam

Pages 182-204

Targeting MYC-driven lymphoma: lessons learned and future directions

Sandra Martínez-Martín

Sandra Martínez-Martín

, ... Laura Soucek

Laura Soucek

Pages 205-222

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

Salvatore Perrone

Salvatore Perrone

, ... Matteo Molica

Matteo Molica

Pages 223-238

Cancer stem cells in drug resistance: an introduction to the e-book covering the special issue on the “Cancer Stem Cells and Drug Resistance”

Balázs Sarkadi

Pages 239-241

miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia

Maryam Zanjirband, ... Narges Aberuyi

Pages 242-256

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

William H. Gmeiner, Charles Chidi Okechukwu

Pages 257-272

Mitochondria in colorectal cancer stem cells - a target in drug resistance

Mateus de Almeida Rainho

Mateus de Almeida Rainho

, ... Alessandra Alves Thole

Alessandra Alves Thole

Pages 273-283

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Yaling Jiang, ... Dong Mei Deng

Pages 284-290

Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer

Sergi Benavente

Sergi Benavente

Pages 291-313

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma

Monica Sheila Chatwal, ... Philippe E. Spiess

Pages 314-326

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

Liia Akhuba

Liia Akhuba

, ... Dmitrii Shek

Dmitrii Shek

Pages 327-331

Importance of ROS1 gene fusions in non-small cell lung cancer

Meri Muminovic, ... Luis E. Raez

Pages 332-344

The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer

Sara Bouberhan, ... Bo R. Rueda

Pages 345-357

Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

Won-Hee Yoon, ... Lawrence Kasherman

Lawrence Kasherman

Pages 358-377

Interaction of pregnane X receptor with hypoxia-inducible factor-1 regulates chemoresistance of prostate cancer cells

Jiuhui Wang, Daotai Nie

Pages 378-389

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Xiangyu Sun, ... Jianliang Shen

Pages 390-415

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors

Sunil Samnani

Sunil Samnani

, ... Vishal Navani

Vishal Navani

Pages 416-429

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells

Gerrit Jansen, ... Godefridus J. Peters

Godefridus J. Peters

Pages 430-446

Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy

Gianluca Santamaria

Gianluca Santamaria

, ... Maria Lucibello

Maria Lucibello

Pages 447-467

The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducers

William J. E. Frye, ... Michael M. Gottesman

Michael M. Gottesman

Pages 468-480

The multifaceted role of extracellular vesicles in prostate cancer-a review

Divya Prakash Jain, ... Vikas Jain

Vikas Jain

Pages 481-498

The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities

Teresa Zielli, ... Ilaria Colombo

Ilaria Colombo

Pages 499-516

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma

Serena Astore, ... Fabio Calabrò

Pages 517-546

A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer

Hiroshi Kobayashi

Hiroshi Kobayashi

, ... Shogo Imanaka

Pages 547-566

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia

Priyanka Sharma

Priyanka Sharma

, Gautam Borthakur

Pages 567-589

New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection

Michael M. Gottesman

Michael M. Gottesman

, ... Suresh V. Ambudkar

Suresh V. Ambudkar

Pages 590-595

Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7

Vera Apollonova, ... Anastasia Malek

Anastasia Malek

Pages 596-610

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment

Kyra Laubach, ... Josue Samayoa

Josue Samayoa

Pages 611-641

Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena

Arya Mariam Roy

Arya Mariam Roy

, Saby George

Pages 642-655

A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer

Kenneth Sooi, ... Natalie Ngoi

Pages 656-673

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia

Lindsay Gurska, Kira Gritsman

Kira Gritsman

Pages 674-687

Drug resistance in glioblastoma: from chemo- to immunotherapy

Sachin Sharma, ... Tao Sun

Tao Sun

Pages 688-708

Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity

Hannah Zaryouh

Hannah Zaryouh

, ... An Wouters

An Wouters

Pages 709-728

Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance

Jia-Wen Chen, ... Guo-Qing Chen

Guo-Qing Chen

Pages 729-747

Unlocking antitumor immunity with adenosine receptor blockers

Victoria A. Remley

Victoria A. Remley

, ... Julien Dimastromatteo

Julien Dimastromatteo

Pages 748-767

Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies

Rachel SJ Wong, ... Joline SJ Lim

Pages 768-787

Emerging roles of 3D-culture systems in tackling tumor drug resistance

Amin Nikdouz

Amin Nikdouz

, Francesca Orso

Francesca Orso

Pages 788-804

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Sha Wu, ... Jiong Zhou

Jiong Zhou

Pages 805-827

Targeting BCL2 pathways in CLL: a story of resistance and ingenuity

Amanda Reyes, Tanya Siddiqi

Tanya Siddiqi

Pages 828-837

Autophagy-related mechanisms for treatment of multiple myeloma

Gül Kozalak

Gül Kozalak

, Ali Koşar

Ali Koşar

Pages 838-857

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

Patrick L. Sweeney, ... Arpita Desai

Pages 858-873

Actions for 0 selected articles

Cancer Drug Resistance

ISSN 2578-532X (Online)

editorial@cdrjournal.com

Navigation

Follow Us

LinkedIn
Twitter
WeChat

Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

partners@oaepublish.com

Discover Content

Language Editing

Layout & Production

Graphical Abstracts

Video Abstracts

Conference Organizer

Strategic Collaborators

Follow OAE

© 2016-2025 OAE Publishing Inc., except certain content provided by third parties

Privacy Cookies Terms of Service